{rfName}
Di

Indexed in

License and use

Altmetrics

Analysis of institutional authors

Valduvieco IAuthorRibal MjAuthorCampos FAuthorCasas FAuthorNicolau, CAuthorMellado BAuthorFuster DAuthorParedes PCorresponding Author
Share
Publications
>
Article

Diagnostic utility and therapeutic impact of PET/CT [18F]F-Fluoromethylcholine -Choline in the biochemical recurrence of prostate cancer

Publicated to:Revista Espanola De Medicina Nuclear E Imagen Molecular. 39 (5): 284-291 - 2020-10-01 39(5), DOI: 10.1016/j.remn.2020.03.010

Authors: Sanchez, N; Valduvieco, I; Ribal, M J; Campos, F; Casas, F; Nicolau, C; Salvador, R; Mellado, B; Jorcano, S; Fuster, D; Paredes, P

Affiliations

CDI Hosp Clin Barcelona, Serv Radiodiagnost, Barcelona, Spain - Author
Hosp Clin Barcelona, Serv Med Nucl, Barcelona, Spain - Author
Hosp Clin Barcelona, Serv Oncol Radioterap, Barcelona, Spain - Author
Hosp Clin Barcelona, Serv Urol, Barcelona, Spain - Author
Hospital Clinic Barcelona - Author
ICMHO Hosp Clin Barcelona, Serv Oncol Med, Barcelona, Spain - Author
Univ Barcelona UB, Fac Med, Barcelona, Spain - Author
Universitat de Barcelona - Author
See more

Abstract

© 2020 Sociedad Española de Medicina Nuclear e Imagen Molecular Objective: To assess the diagnostic capability of PET/CT with [18F]F-Fluoromethylcholine in prostate cancer (PC) with biochemical recurrence and its therapeutic impact. Material and methods: We included 108 patients, diagnosed with PC with biochemical criteria for recurrence. A PET/CT Choline scan was performed by dynamic pelvic and whole body study at 60 min post-tracer injection. The relationship between the positive studies and the PSA value was analysed by classifying patients into three groups (< 1.2/1.2-2/> 2 ng/ml), and the diagnostic capacity was assessed with respect to pelvic MRI and the impact on the therapeutic decision. Results: The location of recurrence was identified in 85 of 108 patients (78.7%): 34 local, 47 pelvic lymph nodes and 58 distant lesions, including retroperitoneal, mediastinal lymph nodes and distant organ lesions (bone and lung). Second tumors were diagnosed in 4 patients. No significant differences were found in the percentage of positive studies depending on primary treatment. Patients with PSA > 2 ng/ml showed a higher percentage of disease detection than patients with a lower PSA level, with significant differences (p < 0.0001). PET/CT [18F]F-Choline was able to detect local disease, not previously known from MRI, in 29.41% of patients. PET/CT Choline had an impact on therapeutic management in 67 of 108 patients (62%). Conclusions: PET/CT with [18F]F-Fluoromethylcholine is a useful tool in the detection of locoregional and disseminated disease of PC treated with suspicion of recurrence, providing a change in therapeutic management in 62% of patients.

Keywords
biochemical recurrencecáncer de próstatapet/ct [(18)f]f-cholinepet/tc [(18)f]f-colinaprostate cancerAdenocarcinomaAgedAged, 80 and overBiochemical recurrenceBone neoplasmsC-11-cholineCancer de prostataCholineDisease managementF-18-choline pet/ctFluorine radioisotopesFluorine-18FluorocholineFluoromethylcholineHumansIncidental findingsKallikreinsKlk3 protein, humanLocal recurrenceLung neoplasmsLymphatic metastasisMagnetic resonance imagingMaleManagementMiddle agedNeoplasm recurrence, localNeoplasms, second primaryPet/ct [ f]f-choline 18Pet/ct [(18)f]f-cholinePet/ct[f-18]f-cholinePet/tc [(18)f]f-colinaPositron emission tomography computed tomographyProspective studiesProstate cancerProstate-specific antigenProstatic neoplasmsPsa doubling timeRadical prostatectomyRadiopharmaceuticalsRecidiva bioquímicaRelapseSensitivity and specificityVelocity

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Revista Espanola De Medicina Nuclear E Imagen Molecular, and although the journal is classified in the quartile Q4 (Agencia WoS (JCR)), its regional focus and specialization in Radiology, Nuclear Medicine & Medical Imaging, give it significant recognition in a specific niche of scientific knowledge at an international level.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 1.02, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions May 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-05-07, the following number of citations:

  • WoS: 2
  • Scopus: 2
  • Europe PMC: 1
  • OpenCitations: 1
Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-05-07:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 13 (PlumX).
Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: Last Author (Paredes Barranco, Pilar).

the author responsible for correspondence tasks has been Paredes Barranco, Pilar.